Cagrilintide: 5mg/ml (2ml vial)

Description

Cagrilintide: The Next-Gen Appetite Suppressant That Works with GLP-1s—Not Against Them

Cagrilintide is a long-acting amylin analogue that complements GLP-1 medications by enhancing satiety, delaying gastric emptying, and directly signaling the brain to reduce hunger. Originally developed for obesity treatment, it’s quickly gaining traction as the ultimate companion peptide to semaglutide and tirzepatide—amplifying fat loss while minimizing plateaus.

Why Patients & Practitioners Are Turning to Cagrilintide:

• Powerful Appetite Suppression – Directly affects the brain’s hunger centers, helping you feel full longer and reducing calorie intake with ease.
• Synergistic with GLP-1s – When stacked with semaglutide or tirzepatide, Cagrilintide may double the weight loss effect through complementary mechanisms.
• Break Through Plateaus – Ideal for those who have hit a weight-loss plateau or who don’t respond fully to GLP-1s alone.
• Supports Sustainable Weight Loss – Reduces the urge to binge, snack, or emotionally eat, helping patients maintain momentum.
• Non-Stimulant, Non-Habit Forming – A safe and effective option for long-term use without the crashes or dependency of traditional appetite suppressants.

Who It’s For:
Anyone on a GLP-1 journey who wants to break through plateaus, control appetite more effectively, or enhance fat loss while preserving lean mass.

Pricing: $350